SS Innovations International, Inc.

SS Innovations International, Inc. entered into an At-the-Market (ATM) Sales Agreement with Virtu Americas LLC on June 18, 2026. This agreement allows the company to sell up to $50 million of its common stock from time to time. The offering is conducted under a shelf registration statement, with Virtu acting as the exclusive sales agent or principal.

SS Innovations International, Inc. furnished an updated company presentation highlighting its surgical robotic technologies and significant growth. The company reported 210 SSi Mantra systems installed across 12 countries and 11,270 multi-specialty surgeries performed as of May 31, 2026. Revenue increased from $5.9 million in 2023 to $42.5 million in 2025, with Q1 2026 revenue reaching $11.1 million. SS Innovations is pursuing global expansion, anticipating EU CE Mark by Q4 2026 and US FDA clearance by Q4 2026 / Q1 2027.

SS Innovations International, Inc. announced the successful completion of the world's longest-distance robotic telesurgery, a heart procedure performed with its SSi Mantra system across approximately 12,500 miles between Guyana and India. This historic event, led by CEO Dr. Sudhir Srivastava, marks a significant milestone in democratizing access to advanced surgical expertise globally. The achievement coincided with the launch of Guyana's National Robotic Surgery Program and its 60th Independence Anniversary, further positioning Guyana as a hub for robotic surgery. The SSi Mantra system, now approved in 14 countries, has been used for 22 cardiac and 173 total telesurgeries.

SS Innovations International, Inc. announced that Milan Rao resigned from his positions as Global Chief Operating Officer and Chief Financial Officer, effective May 25, 2026. The company is currently undertaking a search process to identify and recruit a permanent successor for the Chief Financial Officer role.

SS Innovations International, Inc. reported record first quarter 2026 revenue of $11.1 million, marking a 116.8% increase year-over-year, driven by robust growth in SSi Mantra installations and procedures. The company's net loss narrowed to $3.6 million, and gross margin significantly expanded to 48.0%. Additionally, SS Innovations successfully completed a private placement raising $18.6 million and secured regulatory approvals for its SSi Mantra system in new international markets, with plans to enter the US and EU markets in 2026.

SS Innovations International, Inc. reported a significant increase in revenue and a reduced net loss for the first quarter ended March 31, 2026. Total revenue grew by 116.8% year-over-year, and the net loss per share improved. The company also completed a private placement, raising $18.4 million in net proceeds, which is intended to support growth initiatives and address ongoing going concern issues, despite management's efforts to secure further funding.

SS Innovations International, Inc. announced the successful completion of a long-distance cross-border telesurgery, spanning over 4,500 miles. Dr. Mohit Bhandari remotely performed a robotic gastrojejunostomy on a patient in India from Australia using the SSi Mantra surgical robotic system and the portable SSi MantrAsana tele-surgeon console. This achievement highlights the advanced capabilities of their technology, which aims to democratize access to global surgical expertise, with over 170 telesurgeries already performed.

SS Innovations International, Inc. announced that its SSi Mantra surgical robotic system has successfully performed over 10,500 cumulative surgeries as of April 30, 2026. This significant milestone includes more than 500 cardiac procedures, 170 telesurgeries, and 125 pediatric surgeries. Since its commercial launch in August 2022, the company has expanded its global installed base to over 200 systems across eleven countries, with approximately 2,100 physicians trained on the system for over 170 different types of procedures.

SS Innovations International, Inc. announced that its SSi Mantra surgical robotic system has successfully performed over 10,500 cumulative surgeries as of April 30, 2026. This milestone includes more than 500 cardiac procedures, 170 telesurgeries, and 125 pediatric surgeries, covering over 170 different procedure types. Since its commercial launch in August 2022, the company has trained approximately 2,100 physicians and expanded its global installed base to over 200 systems across eleven countries.

SS Innovations International, Inc. unveiled its vision for several cutting-edge surgical robotic technologies at the Global Multi-Specialty Robotic Surgery Conference (SMRSC 2026) in New Delhi, India. Key innovations include the SSi Vimana Aero Drone System designed for battlefield surgical care, the SSi Avtara Humanoid Surgical Platform leveraging AI for diverse applications, and the SSi Operion Mobile Operating Room for deployable surgical environments. Additionally, the company showcased new single-arm robotic endoscopy and ultrasound assist carts, currently in early clinical validation.